The late-night surge in Bionano Genomics, Inc. (Nasdaq: BNGO) shares reflects this factor

Bionano Genomics, Inc. (Nasdaq: BNGO), shares surged 30.08% to $1.73 in the late hours trading session after on December 28, 2020, Bionano Genomics, Inc. (Nasdaq: BNGO), revealed that Praxis Genomics, LLC had been accredited by the College of American Pathologists (CAP), becoming the first CAP-accredited, CLIA-certified diagnostic lab in the U.S. to offer a whole genome testing method with Saphyr.This test is designed to evaluate postnatal patients for constitutional genetic disorders.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Praxis uses optical genome mapping with the Bionano Saphyr Framework as an option in contrast chromosomal microarray and caryotyping approaches (KT), as they are trying to increase the rate of clinical diagnosis for genetic disorder patients.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Read More

Hence, doctors recommend that sequential rounds of analysis are performed using CMA, KT, repeat expansion testing, and exome sequencing until a pathogenic variant has been identified.

This tiered approach is replaced at Praxis with whole genome analysis using OGM with Saphyr for structural variants (SVs) and next-generation sequencing (NGS) for SNVs.

Most Popular

Related posts